OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press59410.17650/1818-8346-2022-17-4-106-117NEW DIRECTIONS, DIAGNOSTIC OPPORTUNITIES, AND TREATMENT ADVANCESНОВЫЕ НАПРАВЛЕНИЯ, ВОЗМОЖНОСТИ ДИАГНОСТИКИ И УСПЕХИ ЛЕЧЕНИЯNew perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndromeНовые перспективы в лечении пациентов с миелодиспластическим синдромом промежуточного-2 и высокого рискаhttps://orcid.org/0000-0002-0125-864XMorozovaE. V.МорозоваЕ. В.
Russian Federation

6–8 L’va Tolstogo St., Saint Petersburg 197022

197022 Санкт-Петербург, ул. Льва Толстого, 6–8

dr_morozova@mail.ruhttps://orcid.org/0000-0002-8401-0817TsvetkovN. Yu.ЦветковН. Ю.
Russian Federation

6–8 L’va Tolstogo St., Saint Petersburg 197022

197022 Санкт-Петербург, ул. Льва Толстого, 6–8

https://orcid.org/0000-0002-5273-5581BarabanshchikovaM. V.БарабанщиковаМ. В.
Russian Federation

6–8 L’va Tolstogo St., Saint Petersburg 197022

197022 Санкт-Петербург, ул. Льва Толстого, 6–8

https://orcid.org/0000-0002-9032-6885YurovskayaK. S.ЮровскаяК. С.
Russian Federation

6–8 L’va Tolstogo St., Saint Petersburg 197022

197022 Санкт-Петербург, ул. Льва Толстого, 6–8

https://orcid.org/0000-0002-4332-0114MoiseevI. S.МоисеевИ. С.
Russian Federation

6–8 L’va Tolstogo St., Saint Petersburg 197022

197022 Санкт-Петербург, ул. Льва Толстого, 6–8

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaНИИ детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России071120221741061170611202206112022https://oncohematology.abvpress.ru/ongm/article/view/594

Currently, therapeutic tactics in patients with myelodysplastic syndrome is based on risk-adapted therapy followed by allogeneic hematopoietic stem cell transplantation, which remains the only radical method of treatment. for patients who cannot undergo transplantation, the problem of finding new methods of treatment remains urgent. Modern knowledge about the pathogenesis of the disease allows us to get an idea of the key pathways associated with oncogenesis and to develop new epigenetic methods of treatment.

Aim. To consider the therapeutic approaches currently used in the treatment of patients with myelodysplastic syndrome of low and high risk groups, as well as to demonstrate the relevance of the search for new methods of targeted and immunotherapy. In this review, we highlight the achievements in the field of targeted therapy, in particular, the study of the biology of the TIM3 molecule and its ligands, new data from clinical trials of anti-TIM3 monoclonal antibodies.

В настоящее время терапевтическая тактика у пациентов с миелодиспластическим синдромом основана на проведении риск-адаптированной терапии с последующей аллогенной трансплантацией гемопоэтических стволовых клеток, которая остается единственным радикальным методом лечения. Для пациентов, которым невозможно проведение трансплантации, остается актуальной проблема поиска новых методов лечения. Современные знания о патогенезе заболевания позволяют получить представления о ключевых путях, связанных с онкогенезом, и разработать новые эпигенетические методы лечения.В обзоре рассмотрены терапевтические подходы, применяемые в настоящее время при лечении пациентов с миелодиспластическим синдромом групп низкого и высокого риска, а также продемонстрирована актуальность поиска новых методов таргетной и иммунотерапии. Освещены достижения в области таргетной терапии, в частности изучение биологии молекулы TIM3 и ее лигандов, новые данные клинических испытаний моноклональных антител против TIM3.

myelodysplastic syndromehypomethylating agentsTIM3миелодиспластический синдромгипометилирующие агентыTIM3Afanasyev B.V., Zubarovskaya L. Pediatric myelodysplastic syndrome. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2018;5(3):23–35. (In Russ.). DOI: 10.17650/2311­1267­2018­5­3­23­35Афанасьев Б.В., Зубаровская Л.С. Миелодиспластический синдром у детей. Российский журнал детской гематологии и онкологии 2018;5(3):23–35. DOI: 10.17650/2311­1267­2018­53­23­35Greenberg P. The myelodysplastic syndromes. In: Hematology: Basic Principles and Practice. Eds.: R. Hoffman, E. Benz, S. Shattil et al. New York, NY: Churchill Livingstone, 2000. Pp. 1106–1129.Gattermann N. Iron overload in myelodysplastic syndromes (MDS). Int J Hematol 2018;107(1):55–63. DOI: 10.1007/s12185­017­2367­1Vinchi F., Muckenthaler M.U., Da Silva M.C. et al. Atherogenesis and iron: from epidemiology to cellular level. Front Pharmacol 2014;5:94. DOI: 10.3389/fphar.2014.00094Duffy S.J., Biegelsen E.S., Holbrook M. et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 2001;103(23):2799–804. DOI: 10.1161/01. cir.103.23.2799Dayyani F., Conley A.P., Stromet S.S. et al. Cause of death in patients with lower­risk myelodysplastic syndrome. Cancer 2010;116(9):2174–9. DOI: 10.1002/cncr.24984Steensma D.P. Graphical representation of clinical outcomes for patients with myelodysplastic syndromes. Leuk Lymphoma 2016;57(1):17–20. DOI: 10.3109/10428194.2015.1061191Savchenko V.G., Parovichnikova E.N., Kokhno A.V. et al. National clinical guidelines for the diagnosis and treatment of myelodysplastic syndromes adults. Gematologiya i transfuziologiya = Hematology and Transfusiology 2016;61(1–S4):1–32. (In Russ.).Савченко В.Г., Паровичникова Е.Н., Кохно А.В. и др. Национальные клинические рекомендации по диагностике и лечению миелодиспластических синдромов взрослых. Гематология и трансфузиология 2016;61(1–S4):1–32.Garcia­Manero G., Shan J., Faderl S. et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008;22(3):538–43. DOI: 10.1038/sj.leu.2405070Itzykson R., Crouch S., Travaglino E. et al. Early platelet count kinetics has prognostic value in lower­risk myelodysplastic syndromes. Blood Adv 2018;2(16):2079–89. DOI: 10.1182/ bloodadvances.2018020495Mittelman M., Zeidman A. Platelet function in the myelodysplastic syndromes. Int J Hematol 2000;71(2):95–8.Hellstrom­Lindberg E., Gulbrandsen N., Lindberg G. et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony­stimulating factor: significant effects on quality of life. Br J Haematol 2003;120(6):1037–46. DOI: 10.1046/j.1365­2141.2003.04153.xList A., Kurtin S., Roe D.J. et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352(6):549–57. DOI: 10.1056/NEJMoa041668List A., Bennett J., Giagounidis A. et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355(14):1456–65. DOI: 10.1056/NEJMoa061292Steensma D.P. Hematopoietic growth factors in myelodysplastic syndromes. Semin Oncol 2011;38:635–47. DOI: 10.1053/j. seminoncol.2011.04.014Brierley C.K., Steensma D.P. Thrombopoiesis­stimulating agents and myelodysplastic syndromes. Br J Haematol 2015;169(3):309–23. DOI: 10.1111/bjh.13285Mittelman M., Platzbecker U., Afanasyev B. et al. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo­controlled, phase 2 trial. Lancet Haematol 2018;5(1):e34– 43. DOI: 10.1016/S2352­3026(17)30228­4Oliva E.N, Alati C., Santini V. et al. Eltrombopag versus placebo for low­risk myelodysplastic syndromes with thrombocytopenia (EQoL­MDS): phase 1 results of a single­blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol 2017;4(3):e127–36. DOI: 10.1016/S2352­3026(17)30012­1Shastri A., Verma A.K. Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML. Lancet Haematol 2018;5(1):e6–7. DOI: 10.1016/S2352­3026(17)30229­6Villar S., Robin M. Allogeneic stem cell transplantation for MDS. Hematol 2021;2(3):545–55. DOI: 10.3390/hemato2030034Greenberg P., Cox C., LeBeau M.M. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes [published correction appears in Blood 1998;91(3):1100]. Blood 1997;89(6):2079–88.Cataldo V.D., Cortes J., Quintás­Cardama A. Azacitidine for the treatment of myelodysplastic syndrome. Expert Rev Anticancer Ther 2009;9(7):875–84. DOI: 10.1586/era.09.61Berg T., Guo Y., Abdelkarim M. et al. Reversal of p15/INK4b hypermethylation in AML1/ETO­positive and ­negative myeloid leukemia cell lines. Leuk Res 2007;31(4):497–506. DOI: 10.1016/ j.leukres.2006.08.008Kimura S., Kuramoto K., Homan J. et al. Antiproliferative and antitumor effects of azacitidine against the human myelodysplastic syndrome cell line SKM­1. Anticancer Res 2012;32(3):795–8.Stresemann C., Bokelmann I., Mahlknecht U., Lyko F. Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther 2008;7(9):2998–3005. DOI: 10.1158/1535­7163. MCT­08­0411Fabiani E., Leone G., Giachelia M. et al. Analysis of genome­wide methylation and gene expression induced by 5­aza­2­deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. Leuk Lymphoma 2010;51(12):2275–84. DOI: 10.3109/10428194.2010.528093Khan C., Pathe N., Fazal S. et al. Azacitidine in the management of patients with myelodysplastic syndromes. Ther Adv Hematol 2012;3(6):355–73. DOI: 10.1177/2040620712464882Fenaux P., Mufti G.J., Hellstrom­Lindberg E. et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher­risk myelodysplastic syndromes: a randomised, open­label, phase III study. Lancet Oncol 2009;10(3):223–32. DOI: 10.1016/S1470­2045(09)70003­8Gurion R., Vidal L., Gafter­Gvili A. et al. 5­azacitidine prolongs overall survival in patients with myelodysplastic syndrome – a systematic review and meta­analysis. Haematologica 2010;95(2):303–10. DOI: 10.3324/haematol.2009.010611Cheson B.D., Jasperse D.M., Simon R. et al. A critical appraisal of low­dose cytosine arabinoside in patients with acute nonlymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 1986;4(12):1857–64. DOI: 10.1200/JCO.1986.4.12.1857Fenaux P., Haase D., Sanz G.F. et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow­up. Ann Oncol 2014;25(Suppl 3):iii57–69. DOI: 10.1093/annonc/mdu180Kantarjian H., O’brien S., Cortes J. et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high­risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106(5):1090–8. DOI: 10.1002/cncr.21723Schmid C., Wreede L., Biezen A. et al. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. Haematologica 2018;103(2):237–45. DOI: 10.3324/haematol.2017.168716Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252–64. DOI: 10.1038/nrc3239Riva A., Chokshi S. Immune checkpoint receptors: homeostatic regulators of immunity. Hepatol Int 2018;12(3):223–36. DOI: 10.1007/s12072­018­9867­9Darvin P., Toor S.M., Sasidharan N.V. et al. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 2018;50(12):1–11. DOI: 10.1038/s12276­018­0191­1Havel J.J., Chowell D., Chan T.A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 2019;19(3):133–50. DOI: 10.1038/s41568­019­0116­xPagliuca S., Gurnari C., Visconte V. Molecular targeted therapy in myelodysplastic syndromes: new options for tailored treatments. Cancers 2021;13(4):784. DOI: 10.3390/cancers13040784Boddu P., Kantarjian H., Garcia­Manero G. et al. The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma 2018;59(4):790–802. DOI: 10.1080/10428194.201 7.1344905Zeidan A.M., Knaus H.A., Robinson T.M. et al. A multi­center phase I trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure. Clin Cancer Res 2018;24(15):3519–27. DOI: 10.1158/1078­0432.CCR­17­3763Wendelbo O., Nesthus I., Sjo M. et al. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy­induced leukopenia. Cancer Immunol Immunother 2004;53(8):740–7. DOI: 10.1007/s00262­004­0505­0Garcia­Manero G., Sasaki K., Montalban­Bravo G. et al. A phase II study of nivolumab or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome (MDS). Blood 2018;132.Garcia­Manero G., Tallman M.S., Martinell I.G. et al. Pembrolizumab, a PD­1 inhibitor, in patients with myelodysplastic syndrome (MDS) after failure of hypomethylating agent treatment. Blood 2016;128. DOI: 10.1182/blood.V128.22.345.345Davids M.S., Kim H.T., Bachireddy P. et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 2016;375(2):143–53. DOI: 10.1056/NEJMoa1601202Daver N., Boddu P., Garcia­Manero G. et al. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia 2018;32(5):1094–105. DOI: 10.1038/s41375­018­0070­8Khaznadar Z., Henry G., Setterblad N. et al. Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse. Eur J Immunol 2014;44(10):3068–80. DOI: 10.1002/eji.201444500Bewersdorf J.P., Shallis R.M., Zeidan A.M. Immune checkpoint inhibition in myeloid malignancies: moving beyond the PD­1/PD­L1 and CTLA­4 pathways. Blood Rev 2021;45:100709. DOI: 10.1016/j.blre.2020.100709.Chiba S., Baghdadi M., Akiba H. et al. Tumor­infiltrating DCs suppress nucleic acid­mediated innate immune responses through interactions between the receptor TIM3 and the alarmin HMGB1. Nat Immunol 2012;13(9):832–42. DOI: 10.1038/ni.2376Huang Y.H., Zhu C., Kondo Y. et al. CEACAM1 regulates TIM3mediated tolerance and exhaustion. Nature 2015;517(7534):386–90. DOI: 10.1038/nature13848Kikushige Y., Miyamoto T., Yuda J. et al. A TIM3/Gal­9 autocrine stimulatory loop drives self­renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell 2015;17(3):341–52.De Kruyff R.H., Bu X., Ballesteros A. et al. T cell/transmembrane, Ig, and mucin­3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol 2010;184(4):1918–30. DOI: 10.4049/jimmunol.0903059Zhu C., Anderson A.C., Schubart A. et al. The TIM3 ligand galectin­9 negatively regulates T helper type 1 immunity. Nat Immunol 2005;6(12):1245–52. DOI: 10.1038/ni1271Monney L., Sabatos C.A., Gaglia J.L. et al. Th1­specific cell surface protein TIM3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002;415(6871):536–41. DOI: 10.1038/415536aWolf Y., Anderson A.C., Kuchroo V.K. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol 2020;20(3):173–85. DOI: 10.1038/s41577­019­0224­6Wang Y., Zhao E., Zhang Z. et al. Association between Tim3 and Gal9 expression and gastric cancer prognosis. Oncol Rep 2018;40(4):2115–26. DOI: 10.3892/or.2018.6627Gonçalves Silva I., Yasinska I.M., Sakhnevych S.S. et al. The TIM3galectin­9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells. EBioMedicine 2017;22: 44–57. DOI: 10.1016/j.ebiom.2017.07.018Li H., Wu K., Tao K. et al. TIM3/galectin­9 signaling pathway mediates T­cell dysfunction and predicts poor prognosis in patients with hepatitis B virus­associated hepatocellular carcinoma. Hepatology 2012;56(4):1342–51. DOI: 10.1002/hep.25777Cao E., Zang X., Ramagopal U.A. et al. T cell immunoglobulin mucin­3 crystal structure reveals a galectin­9independent ligand­binding surface. Immunity 2007;26(3):311–21. DOI: 10.1016/j.immuni.2007.01.016Kang C.W., Dutta A., Chang L.Y. et al. Apoptosis of tumor infiltrating effector TIM3+CD8+ T cells in colon cancer. Sci Rep 2015;5:15659. DOI: 10.1038/srep15659Kikushige Y., Shima T., Takayanagi S. et al. TIM3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010;7(6):708–17. DOI: 10.1016/j.stem.2010.11.014Kikushige Y., Miyamoto T. TIM3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells. Int J Hematol 2013;98(6):627–33. DOI: 10.1007/s12185­013­1433­6Asayama T., Tamura H., Ishibashi M. et al. Functional expression of TIM3 on blasts and clinical impact of its ligand galectin­9 in myelodysplastic syndromes. Oncotarget 2017;8(51):88904–17. DOI: 10.18632/oncotarget.21492Dama P., Tang M., Fulton N. et al. Gal9/TIM3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer 2019;7(1):175. DOI: 10.1186/s40425­019­0611­3Kong Y., Zhang J., Claxton D.F. et al. PD­1(hi)TIM3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J 2015;5(7):e330. DOI: 10.1038/bcj.2015.58Gonçalves Silva I., Rüegg L., Gibbs B.F. et al. The immune receptor TIM3 acts as a trafficker in a TIM3/galectin­9 autocrine loop in human myeloid leukemia cells. Oncoimmunology 2016;5(7):e1195535. DOI: 10.1080/2162402X.2016.1195535Acharya N., Sabatos­Peyton C., Anderson A.C. TIM3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer 2020;8(1):e000911. DOI: 10.1136/jitc­2020­0091Dardalhon V., Anderson A.C., Karman J. et al. TIM3/galectin­9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly–6G+ myeloid cells. J Immunol 2010;185(3):1383– 92. DOI: 10.4049/jimmunol.0903275Gao X., Zhu Y., Li G. et al. TIM3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One 2012;7(2):e30676. DOI: 10.1371/journal.pone.0030676Jones R.B., Ndhlovu L.C., Barbour J.D. et al. TIM3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV­1 infection. J Exp Med 2008;205(12):2763–79. DOI: 10.1084/jem.20081398Fourcade J., Sun Z., Benallaoua M. et al. Upregulation of TIM3 and PD­1 expression is associated with tumor antigen­specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010;207(10):2175–86. DOI: 10.1084/jem.20100637Sakuishi K., Apetoh L., Sullivan J.M. et al. Targeting TIM3 and PD­1 pathways to reverse T cell exhaustion and restore anti­tumor immunity. J Exp Med 2010;207(10):2187–94. DOI: 10.1084/jem.20100643Yang Z.Z., Grote D.M., Ziesmer S.C. et al. IL­12 upregulates TIM3 expression and induces T cell exhaustion in patients with follicular B cell non­Hodgkin lymphoma. J Clin Invest 2012;122(4):1271–82. DOI: 10.1172/JCI59806Liu J., Zhang S., Hu Y. et al. Targeting PD­1 and TIM3 pathways to reverse CD8 T­cell exhaustion and enhance ex vivo T­cell responses to autologous dendritic/tumor vaccines. J Immunother 2016;39(4):171–80. DOI: 10.1097/CJI.0000000000000122Borate U., Esteve J., Porkka K. et al. Anti­TIM3 antibody MBG453 in combination with hypomethylating agents in patients with highrisk myelodysplastic syndrome and acute myeloid leukemia: a phase 1 study. Paper presented at: 25th EHA Congress. June 11–21, 2020 [abstract S185].